News

A new study conducted by University of Texas Health Science Center at Houston investigators finds that male virgins can still acquire HPV, underscoring the need for vaccination.

Investigators from the Duke Human Vaccine Institute have developed a binding assay capable of more accurately identifying new versus long-standing HIV infections.

Anal high-risk human papillomavirus (HPV) infections are known to lead to anal cancer.

The first step in global health security is prevention, but how does it work against a diverse range of threats?

More states are reporting widespread flu activity as CDC researchers up their annual estimate of flu deaths around the world.

Two recent federal government decisions and actions could put the public at increased risk for an infectious disease outbreak.

The FDA issues a final rule on the safety and effectiveness of certain active ingredients in over-the-counter health care antiseptic products.

One intensive care unit utilized advanced infection control efforts to tackle an outbreak and won.

Individuals with an egg allergy do not need to avoid the annual flu shot.

The expansion in tick populations has led to an increased risk of infection for humans and animals with both established tick-borne agents and newly recognized ones, creating a serious One Health problem.

The Infectious Diseases Society of America’s (IDSA) decision not to endorse the 2016 Surviving Sepsis Campaign Guidelines comes from disagreement on the diagnosis and management of the microbial etiology of the disease.

The US Food and Drug Administration (FDA) has approved Ortho Clinical Diagnostics' VITROS Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator on the VITROS 3600 Immunodiagnostic System.

A surprising source of this opportunistic pathogen was found through environmental testing.

Forty years after the first Ebola outbreak in the Democratic Republic of Congo, investigators find that a small group of survivors are still producing virus-fighting antibodies.

In case you missed them, we've compiled the top 5 articles from this past week.

In case you were wondering what to get the infectious disease (ID) pharmacist in your life for the upcoming holidays.

The results of a new study show that when a best practice advisory (BPA) displayed in the electronic health record of patients in the baby boomer generation, it prompted a 5-fold increase in screening for hepatitis C virus (HCV) in this population.

Hepatitis C is more curable than ever thanks to direct-acting antivirals, and now, a new study shows how expanded access to these drugs through Medicaid is helping more individuals get treated.

Authors of a new Policy Forum suggest an alternative approach to regulating fecal microbiota transplantation.

New CDC study yields higher estimate of seasonal flu-related deaths worldwide.

A new study from investigators at Drexel University revealed that if 25% of high-risk men who have sex with men appropriately used the pre-exposure prophylaxis (PrEP), 3 out of every 10 HIV infections in this population could be prevented.

By making this information available the FDA hopes to help improve patient outcomes, better manage antibiotic use, and decrease antimicrobial resistance.

Investigators from George Mason University have developed another diagnostic method for tuberculosis (TB), a highly sensitive and specific urine test.

As new flu deaths are reported throughout the United States, a pair of studies highlights some of the strengths and weaknesses of the flu shot.

Could forcing pathogens to compete for resources be the key to fighting drug-resistance and extending the lives of existing drugs?

The US Department of Health and Human Services Tick-Borne Disease Working Group held its first public meetings in Washington, DC, this week and it has already generated plenty of eye-grabbing headlines.

Five outbreaks of hepatitis A continue to beat down on several states; can addressing the homelessness crisis prevent future outbreaks from happening?

A new study compares the long-term effects of combination ART (cART) initiation during primary HIV infection with therapy initiation during chronic HIV infection.